There are 2789 resources available
505TiP - REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
Presenter: Giacomo Bregni
Session: ePoster Display
462P - Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer
Presenter: David Tougeron
Session: ePoster Display
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
427P - Real world data of trifluridine/tipiracil in refractory mCRC: A multicenter experience at four GEODA Spanish hospitals
Presenter: Julia Martinez Perez
Session: ePoster Display
428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer
Presenter: Hong Qiu
Session: ePoster Display
Resources:
Abstract
430P - Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer
Presenter: Janet Graham
Session: ePoster Display
Resources:
Abstract
431P - The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)
Presenter: Richard Adams
Session: ePoster Display
471P - Prognostic role of preoperative direct bilirubin-to-indirect bilirubin ratio and neutrophils-to-lymphocytes in resectable colorectal cancer
Presenter: Yifei Ma
Session: ePoster Display